The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE Registry.

Meegdes, Marissa; Geurts, Sandra M E; Erdkamp, Frans L G; Dercksen, Marcus Wouter; Vriens, Birgit E P J; Aaldering, Kirsten N A; Pepels, Manon J A E; van de Winkel, Linda M H; Teeuwen, Nathalie J A; de Boer, Maaike; Tjan-Heijnen, Vivianne C G

Meegdes, Marissa; Geurts, Sandra M E; Erdkamp, Frans L G; Dercksen, Marcus Wouter; Vriens, Birgit E P J; Aaldering, Kirsten N A; Pepels, Manon J A E; van de Winkel, Linda M H; Teeuwen, Nathalie J A; de Boer, Maaike; Tjan-Heijnen, Vivianne C G.

Afiliação

Meegdes M; Department of Internal Medicine, Division of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Geurts SME; Department of Internal Medicine, Division of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Erdkamp FLG; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, The Netherlands.
Dercksen MW; Department of Medical Oncology, Máxima Medical Center, Eindhoven, The Netherlands.
Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands.
Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands.
Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands.
van de Winkel LMH; Department of Internal Medicine, St Anna Hospital, Geldrop, The Netherlands.
Teeuwen NJA; Department of Internal Medicine, Division of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
de Boer M; Department of Internal Medicine, Division of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Tjan-Heijnen VCG; Department of Internal Medicine, Division of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.

Int J Cancer ; 150(1): 124-131, 2022 01 01.

Article em En | MEDLINE | ID: mdl-34460112

Assuntos

Neoplasias da Mama/tratamento farmacológico; Quinase 4 Dependente de Ciclina/antagonistas & inibidores; Quinase 6 Dependente de Ciclina/antagonistas & inibidores; Inibidores de Proteínas Quinases/uso terapêutico; Receptor ErbB-2/metabolismo; Receptores de Estrogênio/metabolismo; Receptores de Progesterona/metabolismo; Adulto; Idoso; Idoso de 80 Anos ou mais; Neoplasias da Mama/epidemiologia; Neoplasias da Mama/metabolismo; Neoplasias da Mama/patologia; Feminino; Seguimentos; Humanos; Pessoa de Meia-Idade; Países Baixos/epidemiologia; Seleção de Pacientes; Prognóstico; Sistema de Registros/estatística & dados numéricos; Estudos Retrospectivos; Taxa de Sobrevida

Palavras-chave

CDK4/6 inhibitors; breast cancer; implementation; metastatic disease; real-world

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Progesterona / Receptores de Estrogênio / Receptor ErbB-2 / Inibidores de Proteínas Quinases / Quinase 4 Dependente de Ciclina / Quinase 6 Dependente de Ciclina Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google